Mettler-Toledo International
MTD
1,533.48
+0.41
+0.03%
Mettler-Toledo International
US · MTD
#673 by market cap
Listed 1970
1,533.48
+0.41
+0.03%
Live - 5344 symbols - heartbeat 166s ago
· 2026-10-08 07:16
Pre-market
1,529.46
-0.26%
After-hours
1,533.48
0.00%
- Market cap
- 30.73B
- P/E (TTM)i
- 34.57
- P/Bi
- 2,396.06
- EPSi
- 42.05
- Div yieldi
- 0.00%
- 52W posi
- 91%
Reader sentiment
Are you bullish or bearish on MTD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 10.55, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +3.98% YoY
Margins
- Gross margin
- 59.37%
- Operating margin
- 27.78%
- Net margin
- 21.59%
Key ratios & quality
- Enterprise valuei
- 32.81B
- Altman Z-Scorei
- 10.55
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.94B | 3.01B | 3.09B | 3.72B | 3.92B | 3.79B | 3.87B | 4.03B |
| Gross profit | 1.68B | 1.74B | 1.80B | 2.17B | 2.31B | 2.24B | 2.33B | 2.39B |
| Selling & admin expenses | 812.80M | 819.18M | 820.22M | 943.98M | 938.46M | 904.11M | 936.30M | 998.31M |
| Research & development | 141.07M | 143.95M | 140.10M | 169.77M | 177.12M | 185.28M | 189.36M | 199.37M |
| Operating profit | 682.98M | 728.39M | 784.04M | 994.74M | 1.13B | 1.08B | 1.13B | 1.12B |
| Pretax profit | 651.86M | 681.39M | 748.74M | 949.36M | 1.07B | 973.73M | 1.04B | 1.05B |
| Tax | 139.25M | 120.29M | 146.00M | 180.38M | 198.09M | 184.95M | 174.08M | 179.72M |
| Net profit | 512.61M | 561.11M | 602.74M | 768.99M | 872.50M | 788.78M | 863.14M | 869.19M |
| Basic EPS | 20 | 23 | 25 | 33 | 39 | 36 | 41 | 42 |
| Diluted EPS | 19.88 | 22.47 | 24.91 | 32.78 | 38.41 | 35.90 | 40.48 | 42.05 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 883.74M | 983.22M | 1.03B | 1.13B | 947.13M | 1.03B |
| Gross profit | 525.88M | 579.88M | 609.46M | 675.44M | 555.82M | 650.22M |
| Selling & admin expenses | 242.80M | 247.30M | 248.39M | 259.83M | 258.33M | 263.33M |
| Research & development | 46.35M | 49.29M | 51.14M | 52.60M | 51.28M | 52.99M |
| Operating profit | 219.54M | 265.71M | 289.90M | 343.34M | 226.60M | 314.47M |
| Pretax profit | 201.94M | 248.66M | 269.24M | 329.07M | 209.66M | 289.40M |
| Tax | 38.36M | 46.31M | 51.74M | 43.31M | 40.20M | 56.50M |
| Net profit | 163.59M | 202.35M | 217.49M | 285.77M | 169.45M | 232.90M |
| Basic EPS | 8 | 10 | 11 | 14 | 8 | 12 |
| Diluted EPS | 7.81 | 9.76 | 10.57 | 13.98 | 8.33 | 11.55 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.05B | 1.11B | 1.06B | 1.27B | 1.38B | 1.23B | 1.19B | 1.36B |
| Cash & ST investments | 178.11M | 207.79M | 94.25M | 98.56M | 95.97M | 69.81M | 59.36M | 66.89M |
| Inventory | 268.82M | 274.29M | 297.61M | 414.54M | 441.69M | 385.87M | 342.27M | 387.23M |
| Total assets | 2.62B | 2.79B | 2.81B | 3.33B | 3.49B | 3.36B | 3.24B | 3.71B |
| Total current liabilities | 734.43M | 754.51M | 840.33M | 1.15B | 1.15B | 1.18B | 1.17B | 1.20B |
| Short-term debt | 49.67M | 55.87M | 50.32M | 101.13M | 106.05M | 192.22M | 182.62M | 63.93M |
| Long-term debt | 985.02M | 1.24B | 1.28B | 1.58B | 1.91B | 1.89B | 1.83B | 2.09B |
| Total liabilities | 2,028,784,000.00 | 2,368,541,000.00 | 2,531,874,000.00 | 3,155,377,000.00 | 3,467,602,000.00 | 3,505,493,000.00 | 3,366,889,000.00 | 3,736,282,000.00 |
| Total equity | 590.06M | 420.78M | 282.68M | 171.42M | 24.79M | -149.94M | -126.89M | -23.64M |
| Retained earnings | 3.94B | 4.50B | 5.10B | 5.86B | 6.73B | 7.51B | 8.37B | 9.24B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.16B | 1.24B | 1.28B | 1.36B | 1.33B | 1.35B |
| Cash & ST investments | 64.29M | 61.83M | 69.07M | 66.89M | 60.57M | 51.38M |
| Inventory | 358.79M | 388.08M | 401.81M | 387.23M | 404.83M | 411.56M |
| Total assets | 3.23B | 3.40B | 3.52B | 3.71B | 3.67B | 3.67B |
| Total current liabilities | 1.15B | 1.11B | 1.19B | 1.20B | 1.11B | 1.20B |
| Short-term debt | 182.86M | 60.19M | 63.61M | 63.93M | 67.04M | 67.29M |
| Long-term debt | 1.89B | 2.12B | 2.15B | 2.09B | 2.16B | 2.04B |
| Total liabilities | 3,416,661,000.00 | 3,659,258,000.00 | 3,770,664,000.00 | 3,736,282,000.00 | 3,710,798,000.00 | 3,658,121,000.00 |
| Total equity | -181.98M | -258.79M | -249.20M | -23.64M | -41.88M | 12.82M |
| Retained earnings | 8.53B | 8.74B | 8.95B | 9.24B | 9.41B | 9.64B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 565.01M | 603.45M | 724.70M | 908.83M | 859.07M | 965.87M | 968.35M | 955.77M |
| Depreciation & amortization | 84.69M | 88.68M | 98.71M | 108.06M | 113.02M | 121.16M | 123.22M | 125.61M |
| Free cash flow | 422.28M | 506.11M | 632.21M | 801.25M | 737.83M | 860.55M | 864.45M | 848.65M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -475.00M | -775.00M | -775.00M | -1,000.00M | -1.10B | -900.00M | -850.00M | -800.00M |
| Ending cash balance | 178.11M | 207.79M | 94.25M | 98.56M | 95.97M | 69.81M | 59.36M | 66.89M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 194.45M | 236.37M | 299.37M | 225.59M | 139.79M | 310.42M |
| Depreciation & amortization | 29.66M | 30.45M | 32.74M | 32.77M | 32.77M | 32.73M |
| Free cash flow | 177.19M | 212.49M | 274.88M | 184.08M | 122.38M | 282.62M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -218.75M | -218.75M | -218.75M | -143.75M | -206.25M | -206.25M |
| Ending cash balance | 64.29M | 61.83M | 69.07M | 66.89M | 60.57M | 51.38M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 90.14 | 111.02 | 171.37 | 338.69 | 889.34 | -- | -- | -- |
| ROA %i | 19.84 | 20.75 | 21.51 | 25.04 | 25.59 | 23.04 | 26.17 | 25.00 |
| ROIC %i | 34.25 | 35.48 | 38.08 | 46.33 | 47.15 | -- | -- | -- |
| 5-year avg ROE %i | 67.51 | 81.54 | 104.96 | 157.55 | 320.11 | -- | -- | -- |
| EBIT margin %i | 23.38 | 23.89 | 25.52 | 26.70 | 28.73 | 27.75 | 28.71 | 27.75 |
| FCF / sales %i | 14.38 | 16.82 | 20.49 | 21.55 | 18.82 | 22.72 | 22.32 | 21.08 |
| Current ratioi | 1.42 | 1.47 | 1.26 | 1.11 | 1.20 | 1.04 | 1.02 | 1.14 |
| Quick ratioi | 0.97 | 1.03 | 0.82 | 0.65 | 0.70 | 0.62 | 0.64 | 0.71 |
| Debt / assetsi | 39.51 | 46.29 | 47.41 | 50.56 | 57.68 | 62.01 | 62.16 | 57.97 |
| LT debt / equityi | 166.93 | 293.59 | 454.29 | 922.18 | 7,697.66 | -- | -- | -- |
| Interest coveragei | 19.89 | 19.21 | 20.39 | 22.95 | 20.33 | 13.59 | 14.90 | 16.31 |
| Revenue CAGR (3Y) %i | 7.01 | 6.25 | 4.22 | 8.19 | 9.22 | 7.08 | 1.37 | 0.90 |
| Net income CAGR (3Y) %i | 13.26 | 13.44 | 17.04 | 14.47 | 15.85 | 9.38 | 3.93 | -0.13 |
| FCF CAGR (3Y) %i | 5.73 | 14.54 | 17.58 | 23.80 | 13.39 | 10.83 | 2.56 | 4.78 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | 26.06 | 24.96 | 24.43 | 25.00 | 25.35 | 25.61 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 28.48 | 28.29 | 27.99 | 27.75 | 27.52 | 28.22 |
| FCF / sales %i | 22.69 | 21.93 | 22.57 | 21.08 | 19.41 | 20.90 |
| Current ratioi | 1.01 | 1.12 | 1.07 | 1.14 | 1.20 | 1.12 |
| Quick ratioi | 0.61 | 0.67 | 0.63 | 0.71 | 0.69 | 0.65 |
| Debt / assetsi | 64.12 | 64.22 | 62.75 | 57.97 | 60.74 | 57.53 |
| LT debt / equityi | -- | -- | -- | -- | -- | 15,945.36 |
| Interest coveragei | 15.14 | 15.65 | 16.00 | 16.31 | 16.34 | 16.83 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Laboratory is the largest reported line at 53.79% of revenue, across 3 reported segments.
- industrial follows at 40.66%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Laboratory53.79%
industrial40.66%
Retail5.55%
Quote time 2026-10-08 07:16:11 · For reference only, not investment advice and not tailored to your situation.